Research Article
Electrocardiographic Characteristics of Breast Cancer Patients Treated with Chemotherapy
Table 1
Baseline clinical characteristics and cardiovascular risk factors in breast cancer patients.
| | Characteristics |
| | Age, years, mean ± SD | 49.09 ± 9.61 | | Females, n (%) | 64 (100) | | BMI, kg/m2 | 24.02 ± 3.18 | | Systolic pressure, mmHg | 124.91 ± 14.86 | | Diastolic pressure, mmHg | 81.63 ± 11.01 |
| | Medical history, n (%) | | Hypertension | 8 (12.50) | | Diabetes mellitus | 3 (4.69) | | Dyslipidemia | 0 (0) | | Coronary heart disease | 2 (3.13) |
| | Smoking, n (%) | | Current smoker | 0 (0) | | Former smoker | 0 (0) | | Nonsmoker | 63 (100) | | HR status, n (%) | | ER− and PR− | 27 (42.19) | | ER+ and/or PR+ | 36 (56.25) | | HER-2+ | 24 (37.50) | | Histology type, n (%) | | Ductal carcinoma | 3 (4.69) | | Lobular carcinoma | 59 (92.19) | | DCIS | 2 (3.13) |
| | Cancer stage, n (%) | | I | 23 (35.94) | | II | 37 (57.81) | | III | 4 (6.25) | | IV | 0 (0) |
| | Surgery, n (%) | | Lumpectomy | 41 (64.06) | | Mastectomy | 23 (35.94) | | Cardiovascular medications, n (%) | | Beta-blockers | 0 (0) | | Calcium channel antagonist | 6 (9.38) | | Antiplatelet medicines | 1 (1.56) | | ACEI/ARBs | 1 (1.56) | | Statins | 0 (0) |
| | Cancer therapy, n (%) | | Anthracycline | 49 (76.56) | | Taxane | 60 (93.75) | | Anti-HER2 | 21 (32.81) | | Anthracycline and anti-HER2 | 15 (23.44) |
| | Cumulative dose of anthracycline, mg | | Median (range) | 354.29 ± 149.22 | | <430 | 37 (57.81) | | ≥430 | 12 (18.75) |
| | Cumulative dose of taxane, mg | | Median (range) | 771.00 ± 345.93 | | <760 | 40 (62.50) | | ≥760 | 20 (31.25) |
| | Endocrine therapy, n (%) | | AI | 16 (25.00) | | TAM | 20 (31.25) | | None | 28 (43.75) |
|
|
BMI, body mass index; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HER2, human epidermal growth factor receptor 2; DCIS, ductal carcinoma in situ; AI, aromatase inhibitor; BMI, body mass index; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor; TAM, tamoxifen.
|
